Literature DB >> 3312013

Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a.

L S Baron1, D J Kopecko, S B Formal, R Seid, P Guerry, C Powell.   

Abstract

For protection against dysentery caused by Shigella flexneri 2a, an in vivo-constructed recombinant plasmid with genes specifying the S. flexneri type and group antigens located near the pro (min 6) and his (min 44) chromosomal markers, respectively, was made and transferred to the galE Salmonella typhi strain Ty21a. Strain Ty21a carrying this recombinant plasmid was shown by immunological and biochemical analyses to express the S. flexneri 2a type and group antigens. Mice immunized with this vaccine strain were found to be protected against challenge with virulent S. flexneri 2a, but not significantly against S. typhi challenge, presumably because synthesis of the Shigella antigens interfered with expression of the typhoid antigens. Elimination of the recombinant plasmid from Ty21a allowed this strain to again express typical S. typhi O antigens. Mouse protection against both S. typhi and S. flexneri 2a challenges was achieved with a whole-cell vaccine mixture composed of equal parts of Ty21a and the Ty21a-S. flexneri 2a hybrid strain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312013      PMCID: PMC259979          DOI: 10.1128/iai.55.11.2797-2801.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  8 in total

1.  Bacteriophage Mu-1: a tool to transpose and to localize bacterial genes.

Authors:  M Faelen; A Toussaint
Journal:  J Mol Biol       Date:  1976-07-05       Impact factor: 5.469

2.  A controlled field trial of liver oral typhoid vaccine Ty21a.

Authors:  M H Wahdan; C Serie; R Germanier; A Lackany; Y Cerisier; N Guerin; S Sallam; P Geoffroy; A S el Tantawi; P Guesry
Journal:  Bull World Health Organ       Date:  1980       Impact factor: 9.408

3.  Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine.

Authors:  R H Gilman; R B Hornick; W E Woodard; H L DuPont; M J Snyder; M M Levine; J P Libonati
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

4.  Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen.

Authors:  R C Seid; D J Kopecko; J C Sadoff; H Schneider; L S Baron; S B Formal
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

5.  Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain.

Authors:  S B Formal; L S Baron; D J Kopecko; O Washington; C Powell; C A Life
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

6.  Genetic and physical evidence for plasmid control of Shigella sonnei form I cell surface antigen.

Authors:  D J Kopecko; O Washington; S B Formal
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

7.  Genetic Transfer of Shigella flexneri Antigens to Escherichia coli K-12.

Authors:  S B Formal; P Gemski; L S Baron; E H Labrec
Journal:  Infect Immun       Date:  1970-03       Impact factor: 3.441

8.  Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.

Authors:  R E Black; M M Levine; M L Clements; G Losonsky; D Herrington; S Berman; S B Formal
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

  8 in total
  7 in total

Review 1.  Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens.

Authors:  L Cárdenas; J D Clements
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

Review 2.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

3.  Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.

Authors:  S R Klee; B D Tzschaschel; I Fält; A Kärnell; A A Lindberg; K N Timmis; C A Guzmán
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 4.  Oral vaccination.

Authors:  G Dougan; D Maskell; D O'Callaghan; S Chatfield; I Charles; C Hormaeche
Journal:  Antonie Van Leeuwenhoek       Date:  1988       Impact factor: 2.271

5.  Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a.

Authors:  C O Tacket; B Forrest; R Morona; S R Attridge; J LaBrooy; B D Tall; M Reymann; D Rowley; M M Levine
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

6.  Cloning and surface expression of Pseudomonas aeruginosa O antigen in Escherichia coli.

Authors:  J B Goldberg; K Hatano; G S Meluleni; G B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

7.  Attenuated Salmonella enterica Serovar Typhimurium, Strain NC983, Is Immunogenic, and Protective against Virulent Typhimurium Challenges in Mice.

Authors:  Bryan Troxell; Mary Mendoza; Rizwana Ali; Matthew Koci; Hosni Hassan
Journal:  Vaccines (Basel)       Date:  2020-11-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.